Since its founding in 1955, REYON Pharmaceutical has continued to innovate and take new leaps forward. Based on our research, production, and sales capabilities from API to Drug product using purely our own technology, we are leaping to become the global No. 1 bio & chemical pharmaceutical company in various areas including next-generation biopharmaceuticals, from gene therapy, to antibody therapy, cell therapy, and natural medicine.

APIs : We focus on developing high-value drug substances, with a particular emphasis on antibiotics for MRSA (Methicillin-resistant Staphylococcus aureus) and antiviral drugs. These efforts are aimed at addressing critical healthcare needs and responding to emerging global health challenges. Synthetic New Drugs : Our synthetic drug development leverages organic synthesis technologies to create new drug substances. This includes the strategic combination of drugs to enhance therapeutic efficacy, demonstrating our commitment to innovation and effectiveness in treatment solutions. Contrast Agents : We are also pioneering the development of new x-ray contrast agents. This initiative is geared towards improving diagnostic accuracy and patient outcomes in medical imaging, reflecting our dedication to advancing medical technology. Gene Therapy Drugs : In the realm of gene therapy, we are developing therapies based on plasmid DNA (pDNA), messenger RNA (mRNA), adeno-associated virus (AAV), and lentivirus (Lenti) platforms. These therapies are designed to treat rare, chronic, and intractable diseases, utilizing cutting-edge genetic engineering to target diseases at their genetic roots. Cell Therapy: Our cell therapy research focuses on customized treatments for rare and intractable diseases, including the development of natural killer (NK) cell therapies aimed at treating solid tumors. This approach represents a targeted strategy to enhance the precision and effectiveness of cancer treatments. Gene Therapy Platform and Drug Delivery System : We are committed to developing a safe and effective delivery platform for gene therapies, which includes viral vectors and innovative drug delivery systems like ElectroPorators and specialized formulations. This technology is crucial for ensuring that therapeutic genes reach their target cells efficiently and safely. Antibody Therapy : In antibody therapy, our research is directed towards creating therapeutic agents that act specifically on targeted anomalies within the body, thereby minimizing side effects. This specificity is fundamental to improving patient quality of life and treatment outcomes.

Public

Pharma, CDMO, Bio